COMMUNIQUÉS West-GlobeNewswire

Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing

05/11/2018 - 11:30

Sunnyvale, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform [...]

Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)

05/11/2018 - 11:16

Press release 5 November, 2018 Bulletin from Extraordinary General Meeting in Enzymatica AB (publ) Today's Extraordinary General Meeting in Enzymatica AB (publ) resolved to approve the Board of Directors' resolution on [...]

William Demant Holding A/S: Financial calendar 2019

05/11/2018 - 09:54

Company announcement no 2018-10 5 November 2018 Financial calendar 2019 The following dates for publication of the Company’s Annual Report, Interim Report and Interim Management Statements as well as holding of the [...]

Biohit Oyj B-shares Subscribed with Stock Options I 2013

05/11/2018 - 08:30

Biohit Oyj Stock Exchange Release November 5, 2018 at 09.30 a.m. (EEST) A total number of 52,709 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 5 June 2018 and 8 September 2018. These [...]

Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018

05/11/2018 - 07:30

MODI’IN, Israel and MANASQUAN, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of [...]

Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms

05/11/2018 - 07:01

26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021 AVXS101 in SMA type 1 on [...]

ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018

05/11/2018 - 07:00

LYON, France and CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug [...]

ERYTECH tiendra un colloque avec des leaders d’opinion retransmis en direct le 7 novembre 2018

05/11/2018 - 07:00

LYON, France et CAMBRIDGE, Mass., 05 nov. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), société biopharmaceutique de stade clinique développant des thérapies innovantes à partir de sa [...]

Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes

05/11/2018 - 00:42

Read the full release Boston, US, 2 April 2016 - Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide [...]

Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment

05/11/2018 - 00:41

Read the full release Boston, US, 2 April 2016 - Findings from a clinical trial comparing Victoza ® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from [...]

Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo

05/11/2018 - 00:40

Read the full release with references in PDF Boston, US, 4 April 2016 - Today, new data from the three-year part of the phase 3a SCALE(TM) ( S atiety and C linical A diposity - L iraglutide E vidence) Obesity and [...]

Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes

05/11/2018 - 00:39

Read the full release with references Orlando, US, 27 May 2016 - Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with [...]

Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors

05/11/2018 - 00:37

Read the full release Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and [...]

Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100

05/11/2018 - 00:31

New Orleans, US, 11 June 2016 - New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba ® (insulin degludec injection U-100) resulted in significantly lower rates of [...]

Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes

05/11/2018 - 00:30

New Orleans, US, 12 June 2016 - Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76 th [...]

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)

05/11/2018 - 00:30

Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New Orleans, US, 13 June 2016 - New phase 3a findings showed that faster-acting insulin aspart demonstrated a [...]

Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial

05/11/2018 - 00:29

New Orleans, US, 13 June 2016 - Novo Nordisk today announced that Victoza ® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction ( [...]

Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...

05/11/2018 - 00:26

Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with insulin glargine U100 Munich, Germany [...]

Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone or with metformin in adults with type 2 diabetes

05/11/2018 - 00:25

Munich, Germany, 13 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared [...]